# Clinical Trials Data KIT - Document 74

# "One-step" Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions

## Clinical Trial: https://clinicaltrials.gov/study/NCT02005861

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Clinical diagnosis of Osteochondral lesions of the talar dome\n\* Presence of lesion classified as ICRS grade III or IV\n\* size of the lesion \\>1.5 cm2\n\* age \\<50 years\n\nExclusion Criteria:\n\n\* Presence of osteoarthritis\n\* presence of concomitant tibial lesion\n\* presence of ankle malalignment\n\* presence of ankle instability\n\* presence of rheumatic diseases",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "13 Years",  
"stdAges": [  
"CHILD",  
"ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial is for osteochondral lesions of the talar dome. The inclusion/exclusion criteria listed do \*not\* mention anything about KIT gene mutations. Therefore, having a KIT gene mutation is neither explicitly included nor excluded. A patient \*could\* be eligible if they met all other inclusion criteria and none of the exclusion criteria, regardless of their KIT gene status.  
  
It's important to note that this doesn't mean the trial is \*appropriate\* for someone with a KIT mutation. Since it's not mentioned, the trial may not have been designed to consider the potential impact of this mutation. The patient would need to discuss this with their doctor and the trial investigators to determine if participation is safe and advisable.